Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide + decitabine + etoposide for relapsed/refractory adult acute myeloid leukemia
ChiCTR1800015332Phase 2Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat, decitabine and etoposide in acute myeloid leukemia (AML), sponsored by Ruijin Hospital. Primary endpoints: Complete remission rate and Mortality related to study drug. Started Apr 2018; status: recruiting.
02
Drugs
tucidinostatdecitabineetoposide
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR1800015332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800015332.